Diammonium Glycyrrhizinate Capsules (Tongda Moxing) – 50?mg × 9 Capsules

Diammonium Glycyrrhizinate Capsules (Tongda Moxing) – 50?mg × 9 Capsules

$2.00

Tongda Moxing Diammonium Glycyrrhizinate Capsules deliver 50?mg per capsule, with 9 capsules per box. Produced by Shanxi Tongda Pharmaceutical Co., Ltd., and approved under NMPA H20143422. Designed for liver-protective research, particularly in models of acute or chronic hepatitis with elevated ALT.
?? For laboratory and research use only. Not for clinical or diagnostic use.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

Description

Diammonium Glycyrrhizinate is the ammonium salt of glycyrrhizic acid, extracted from licorice root. It exhibits strong hepatoprotective, anti-inflammatory, and membrane-stabilizing properties. Studies have shown it effectively reduces ALT/AST levels and improves liver functions in acute and chronic hepatitis patients . Tongda’s formulation is an enteric-coated capsule designed for preclinical research involving liver injury, viral hepatitis models, enzyme modulation, antioxidation, and fibrotic prevention.


Product Specifications

ParameterDetails
Product NameDiammonium Glycyrrhizinate Capsules (Tongda Moxing)
Generic NameDiammonium Glycyrrhizinate
CAS NumberNot listed (derivative of glycyrrhizic acid)
Dosage FormCapsules
Strength50?mg per capsule
Quantity9 capsules per box
FormulationEnteric-coated capsule
Approval NumberH20143422 (NMPA China)
ManufacturerShanxi Tongda Pharmaceutical Co., Ltd.
Barcode6933290824749
Storage ConditionsStore sealed in dry place, 10–30?°C
Intended UseLaboratory hepatoprotective research, acute/chronic hepatitis models

Mechanism of Action

Diammonium Glycyrrhizinate stabilizes hepatocyte membranes, reduces inflammation, and modulates immunity. It has been shown to significantly lower ALT/AST in viral hepatitis and reduce liver cell damage through anti-inflammatory pathways


Research Applications

  • Modeling acute and chronic viral hepatitis

  • Studies on ALT/AST modulation and liver enzyme regulation

  • Anti-inflammatory and antioxidant mechanism exploration

  • Liver fibrosis prevention and membrane integrity models

  • Comparative preclinical evaluation with other licorice derivatives


Safety & Handling

  • For research use only, not for clinical use

  • Mild adverse events clinically include gastrointestinal discomfort, rash, and fluid retention

  • Avoid use in low potassium, hypertension, heart failure, pregnant women

  • Use PPE; store sealed and discard if capsules deteriorate


Core Keywords

diammonium glycyrrhizinate capsules, licorice-derived hepatoprotection, H20143422, antiviral hepatitis research compound, Tongda Moxing glycyrrhizinate, liver injury model reagent


Research Use Disclaimer

This product is strictly for laboratory and preclinical research use. It is not approved for diagnostic, therapeutic, clinical, or veterinary use. Improper use may pose health or regulatory risks. Use only under appropriate institutional protocols.

Additional information

Weight1 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Diammonium Glycyrrhizinate Capsules (Tongda Moxing) – 50?mg × 9 Capsules”

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare